New shingles vaccine trial aims to protect vulnerable kids
NCT ID NCT04006808
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new shingles vaccine (PED-HZ/su) in children aged 1 to 17 who have had a kidney transplant and have weakened immune systems. The vaccine is given as two shots in the arm. Researchers are checking how safe it is, what side effects occur, and how well it boosts the body's defenses against the shingles virus. The trial involves 184 participants and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PED-HZ/su (shingles vaccine candidate)
- What this could lead to
- If it works, this could provide a safe way to prevent shingles in children with weakened immune systems after a kidney transplant.
- What could go wrong
- This is an early (Phase 1/2) study with only 184 participants, so results may not apply to all. The vaccine could cause side effects like pain, fever, or rarely, more serious issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
RECRUITINGBrussels, 1020, Belgium
-
GSK Investigational Site
RECRUITINGGhent, 9000, Belgium
-
GSK Investigational Site
RECRUITINGLeuven, 3000, Belgium
-
GSK Investigational Site
RECRUITINGLiège, 4000, Belgium
-
GSK Investigational Site
RECRUITINGBordeaux, 33000, France
-
GSK Investigational Site
RECRUITINGLille, 59000, France
-
GSK Investigational Site
RECRUITINGMarseille, 13385, France
-
GSK Investigational Site
RECRUITINGMontpellier, 34295, France
-
GSK Investigational Site
WITHDRAWNNantes, 44093, France
-
GSK Investigational Site
RECRUITINGParis, 75015, France
-
GSK Investigational Site
RECRUITINGParis, 75019, France
-
GSK Investigational Site
RECRUITINGToulouse, 31059, France
-
GSK Investigational Site
COMPLETEDGenova, 16147, Italy
-
GSK Investigational Site
RECRUITINGMilan, 20122, Italy
-
GSK Investigational Site
RECRUITINGPadova, 35128, Italy
-
GSK Investigational Site
RECRUITINGRoma, 00165, Italy
-
GSK Investigational Site
RECRUITINGTorino, 10126, Italy
-
GSK Investigational Site
RECRUITINGGdansk, 80-952, Poland
-
GSK Investigational Site
RECRUITINGBaracaldoVizcaya, 48903, Spain
-
GSK Investigational Site
COMPLETEDEspluges de Llobregat, 08950, Spain
-
GSK Investigational Site
RECRUITINGHebrOn, 08035, Spain
-
GSK Investigational Site
RECRUITINGMadrid, 28007, Spain
-
GSK Investigational Site
RECRUITINGMadrid, 28046, Spain
-
GSK Investigational Site
RECRUITINGSeville, 41013, Spain
-
GSK Investigational Site
COMPLETEDBirmingham, B4 6NH, United Kingdom
-
GSK Investigational Site
COMPLETEDCardiff, CF14 4XW, United Kingdom
-
GSK Investigational Site
RECRUITINGGlasgow Strathclyde, G51 4TF, United Kingdom
-
GSK Investigational Site
RECRUITINGLondon, WC1N 3JH, United Kingdom
-
GSK Investigational Site
RECRUITINGManchester, M13 9WL, United Kingdom
-
GSK Investigational Site
RECRUITINGNottingham, NG7 2UH, United Kingdom
-
GSK Investigational Site
RECRUITINGSouthampton, SO16 6YD, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mRNA technology outsmart shingles? a new vaccine trial aims to find out
- Shingles in cancer patients: a hidden cost burden?
- Shingles vaccine protection tested over 6 years in 24,740 adults
- New gel promises shingles pain relief in minutes
- Shingles shot may shield brain: 33,000 seniors test dementia link
- New shingles vaccine trial aims to protect millions over 40